Evidence map›Paper›PMID 40005226›Full record

ArticleMolecules (Basel, Switzerland)2025

Physalin F, a Potent Inhibitor of Lymphocyte Function, Is a Calcineurin Inhibitor and Has Synergistic Effect with Dexamethasone.

Dahara Keyse Carvalho Silva, Laura Beatriz da Cruz Novo, Ivone Maria Ribeiro, Breno Cardim Barreto, Luiza Carolina França Opretzka, Cássio Santana Meira, Milena Botelho Pereira Soares

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dahara Keyse Carvalho SilvaGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador 40296-710, BA, Brazil.
Laura Beatriz da Cruz NovoGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador 40296-710, BA, Brazil.
Ivone Maria RibeiroLaboratory of Natural Products Chemistry-PN2, Farmanguinhos, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 22775-903, RJ, Brazil.
Breno Cardim BarretoInstitute for Innovation in Advanced Health Systems, National Service for Industrial Learning-Integrated Center for Manufacturing and Technology (SENAI CIMATEC), Salvador 41650-010, BA, Brazil.
Luiza Carolina França OpretzkaInstitute for Innovation in Advanced Health Systems, National Service for Industrial Learning-Integrated Center for Manufacturing and Technology (SENAI CIMATEC), Salvador 41650-010, BA, Brazil.ORCID 0000-0002-7941-6855
Cássio Santana MeiraGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador 40296-710, BA, Brazil.
Milena Botelho Pereira SoaresGonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador 40296-710, BA, Brazil.

Funding

FIOCRUZ, Call for projects in innovative products (2018). 98312864234
6 · The paper itself

Abstract

The dysregulation of immune responses are responsible for the development of several diseases, such as allergic and autoimmune diseases. The medications used to treat these conditions have numerous side effects, creating the need for new drugs. Physalins are natural compounds with various pharmacological activities already described. Here, we aimed to investigate the immunomodulatory effects of physalin F in mouse splenocytes and in a delayed-type hypersensitivity (DTH) model. In a cytotoxicity assay, physalin F had low cytotoxicity to mouse splenocytes in concentrations equal to or below 2 µM. It significantly inhibited lymphocyte proliferation in a concentration-dependent manner and reduced the production of cytokines, including IL-2, IL-4, IL-10, and IFN-γ, in activated splenocytes. The combined therapy of physalin F with dexamethasone was investigated in vitro, showing a synergistic action of the two compounds. Mechanistically, physalin F reduced calcineurin activity in concanavalin A-stimulated splenocyte cultures. Finally, in vivo, the intraperitoneal administration of physalin F in a DTH model reduced paw edema induced by bovine serum albumin immunization. Our results demonstrate the potential of physalin F as an immunosuppressive agent, to be used alone or in combination with glucocorticoids.

Indexed as

Calcineurin InhibitorsDexamethasoneLymphocytesSecosteroidsAnimalsCell ProliferationCytokinesDrug SynergismHypersensitivity, DelayedLymphocyte ActivationMiceSpleenCalcineurin InhibitorsCytokinesDexamethasoneSecosteroidscombination therapyimmunomodulationlymphocytesphysalin F

Identifiers

PMID40005226
PMCPMC11858416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.